Table 3.
The levels of IL-8 and TNF-α in BALF and serum (ng/L) (x̅±s)
| Group | n | BALF (ng/L) | Serum (ng/L) | ||
|---|---|---|---|---|---|
|
|
|
||||
| IL-8 | TNF-α | IL-8 | TNF-α | ||
| Healthy control group | 10 | 63.79±3.42 | 110.39±9.38 | 99.16±2.23 | 240.70±6.68 |
| COPD model group | 10 | 127.70±9.32* | 280.81±4.48* | 153.82±2.21* | 436.76±3.33* |
| Budesonide group | 10 | 80.31±3.71† | 170.78±12.51† | 134.97±2.67‡ | 398.68±7.71‡ |
| Erythromycin group | 10 | 64.97±3.05† | 117.59±10.71† | 110.60±4.33† | 275.00±8.28† |
| Erythromycin + budesonide group | 10 | 65.47±2.29†,§,** | 116.86±6.64†,§,** | 102.11±2.35†,§,*** | 252.15±7.95†,§,*** |
*
Compared with healthy control group, P<0.05;
†
Compared with COPD model group, P<0.05;
§
Compared with budesonide group, P<0.05;
‡
Compared with COPD model group, P=0.693 and 0.505;
**
Compared with erythromycin group, P=0.787, 0.902;
***
Compared with erythromycin group, P<0.05.